Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lipid Modifying Drugs on HDL Function in Hyperlipidemia
NCT02942602Completed
- Sponsor
- Yonsei University
- Start
- Apr 2014
- Primary completion
- May 2016
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Randomised, open-label trial of atorvastatin, cholestyramine, omega-3 fatty acid and ezetimibe in hyperlipidemia (5 arms), sponsored by Yonsei University. Primary endpoints: Cholesterol efflux capacity at 8 weeks, Endothelial NO production at 8 weeks and 2 more. Started Apr 2014; status: completed.
02
Drugs
atorvastatincholestyramineomega-3 fatty acidezetimibe
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT02942602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942602.